XML 117 R103.htm IDEA: XBRL DOCUMENT v3.22.4

Subsequent Events (Details) - Subsequent event - USD ($) $ in Millions		1 Months Ended
	Feb. 22, 2023	Jan. 31, 2023
Tmunity Therapeutics
Subsequent Event [Line Items]
Cash consideration	$ 300
Arcellx, Inc | Global Strategic Collaboration Agreement
Subsequent Event [Line Items]
Payments to acquire in process research and development		$ 225
Payments to acquire shares		$ 100
Percentage of profits earned		50.00%
Arcellx, Inc | Global Strategic Collaboration Agreement | Arcellx, Inc
Subsequent Event [Line Items]
Percentage of profits earned		50.00%

X

- Definition

Payments For Asset Acquisitions

+ References

No definition available.

+ Details

Name:	gild_PaymentsForAssetAcquisitions
Namespace Prefix:	gild_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

X

- Definition

Revenue, Performance Obligation, Percentage Of U.S. Profits

+ References

No definition available.

+ Details

Name:	gild_RevenuePerformanceObligationPercentageOfUSProfits
Namespace Prefix:	gild_
Data Type:	dtr-types:percentItemType
Balance Type:	na
Period Type:	instant

X

- Definition

Amount of cash outflow to acquire investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI), classified as investing activity.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 321
-SubTopic 10
-Section 45
-Paragraph 1
-URI https://asc.fasb.org/extlink&oid=123583714&loc=SL75117360-209713

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 19
-URI https://asc.fasb.org/extlink&oid=126954810&loc=d3e3444-108585

+ Details

Name:	us-gaap_PaymentsToAcquireEquitySecuritiesFvNi
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

X

- Definition

The cash outflows from the purchase of net carrying value allocated to in-process research and development costs and materials acquired in a business combination.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 13
-Subparagraph (b)
-URI https://asc.fasb.org/extlink&oid=126954810&loc=d3e3213-108585

+ Details

Name:	us-gaap_PaymentsToAcquireInProcessResearchAndDevelopment
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

X

- Definition

Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event.

+ References

No definition available.

+ Details

Name:	us-gaap_SubsequentEventLineItems
Namespace Prefix:	us-gaap_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration

X

- Details

Name:	us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	us-gaap_AssetAcquisitionAxis=gild_TmunityTherapeuticsMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=gild_ArcellxIncMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	us-gaap_TypeOfArrangementAxis=gild_GlobalStrategicCollaborationAgreementMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	dei_LegalEntityAxis=gild_ArcellxIncMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type: